Carmell Therapeutics Statistics
Total Valuation
CTCX has a market cap or net worth of $42.50 million. The enterprise value is $41.72 million.
| Market Cap | 42.50M |
| Enterprise Value | 41.72M |
Important Dates
The next estimated earnings date is Tuesday, May 14, 2024, before market open.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCX has 20.73 million shares outstanding. The number of shares has increased by 527.34% in one year.
| Shares Outstanding | 20.73M |
| Shares Change (YoY) | +527.34% |
| Shares Change (QoQ) | -40.84% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.63 |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.09 |
Financial Efficiency
Return on equity (ROE) is -1,325.20% and return on invested capital (ROIC) is -22.11%.
| Return on Equity (ROE) | -1,325.20% |
| Return on Assets (ROA) | -38.10% |
| Return on Capital (ROIC) | -22.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.79M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.84% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -79.84% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 3.18 |
| Relative Strength Index (RSI) | 40.53 |
| Average Volume (30 Days) | 6,747 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.94M |
| Pretax Income | -15.45M |
| Net Income | -16.12M |
| EBITDA | -14.47M |
| EBIT | -14.59M |
| Earnings Per Share (EPS) | -$1.46 |
Balance Sheet
The company has $2.91 million in cash and $2.14 million in debt, giving a net cash position of $776,012 or $0.04 per share.
| Cash & Cash Equivalents | 2.91M |
| Total Debt | 2.14M |
| Net Cash | 776,012 |
| Net Cash Per Share | $0.04 |
| Equity / Book Value | 24.75M |
| Book Value Per Share | 1.19 |
| Working Capital | 24.40M |
Cash Flow
In the last 12 months, operating cash flow was -$8.35 million and capital expenditures -$30,470, giving a free cash flow of -$8.38 million.
| Operating Cash Flow | -8.35M |
| Capital Expenditures | -30,470 |
| Free Cash Flow | -8.38M |
| FCF Per Share | -$0.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -527.34% |
| Shareholder Yield | -527.34% |
| Earnings Yield | -37.93% |
| FCF Yield | -19.72% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |